Recent developments in the pharmacological treatment of Crohn’s disease

Abstract

Therapy for Crohn’s disease (CD) is rapidly evolving with the emergence of new discoveries in disease pathogenesis. Since the approval of the first biological agent, infliximab, there have been several others that have been studied and are available for use within the context of clinical trials, in CD patients who do not respond to conventional medications or whose disease cannot be maintained in remission with the use of infliximab. The number of available drugs that have focused on the inhibition of TNF is growing. To avoid the injectable route of administering biologicals, several oral agents, such as thalidomide analogues, nonabsorbable antibiotics, such as rifaximin, and specific antibiotics, such as ornidazole, are being studied and considered for patients with CD. Hormonal therapies, such as growth hormone, coherin, medroxyprogesterone acetate and dehydroepiandrosterone, are other novel therapies for CD. Immunomodulators in use in other fields of medicine, including tacrolimus, 6-thioguanine and leflunomide, are being evaluated for the treatment of patients with CD and are also discussed. Several other promising therapies, such as cyclophosphamide, extracorporeal photochemotherapy, stem cell transplantation and the use of porcine whipworm, add to the available therapeutic armamentarium of this life-long remitting and relapsing disease. The future for CD patients is promising with the ever-expanding repertoire of drugs that are being studied.

• biologicals
• Crohn’s disease
• inflammatory bowel disease
• management
• novel therapies
• transplantation
• treatment